Literature DB >> 21058043

Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine.

Noriko Takeuchi1, Emi Takenoshita, Fumino Kato, Tomoko Terajima, Makoto Ogawa, Satoshi Suzuki, Takayuki Fujii, Eriko Kobayashi, Tomoya Sakurada, Nobunori Satoh, Shiro Ueda.   

Abstract

BACKGROUND: The evaluation of the progression of renal insufficiency, or decline in glomerular filtration rate (GFR), has been approached more simply and precisely by converting measured serum creatinine value into the reciprocal of serum creatinine, estimated GFR, or other parameters. Doubling of serum creatinine (simple doubling) is conveniently used as a surrogate endpoint for progression of renal disease but is thought to be biased unfairly by the initial value of serum creatinine (Scr(Int)). We proposed the definite decline in the reciprocal of serum creatinine (2-4 doubling) as a surrogate endpoint, comparing simple doubling with this new endpoint to verify the effect of Scr(Int) on the endpoint.
METHODS: For the purpose of comparison between endpoints, 194 patients in a historical cohort of chronic glomerulonephritis were investigated. Kaplan-Meier survival analysis was performed with the composite endpoint of need for dialysis and either simple doubling or 2-4 doubling. Then, the distribution of Scr(Int) was compared between total patients and patients developing each endpoint.
RESULTS: The endpoint value of serum creatinine (Scr(End)) with 2-4 doubling was lower than that with simple doubling at Scr(Int) <2.00 mg/dl, and the difference of Scr(End) between simple doubling and 2-4 doubling was larger, as Scr(Int) became lower. In patients reaching simple doubling, Scr(Int) was higher than that of the total patients (1.66 vs. 1.07 mg/dl in median, respectively; p < 0.001). In patients reaching 2-4 doubling, there was no significant difference in Scr(Int).
CONCLUSION: Patients with low serum creatinine concentration at baseline had a tendency of prolonged development into simple doubling. In contrast, with 2-4 doubling, there was no bias of Scr(Int).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21058043     DOI: 10.1007/s10157-010-0365-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  17 in total

Review 1.  Surrogate end points for clinical trials of kidney disease progression.

Authors:  Lesley A Stevens; Tom Greene; Andrew S Levey
Journal:  Clin J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 8.237

2.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

Review 3.  How to assess the rate of progression of chronic renal failure in children?

Authors:  N M Gretz
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

4.  A simple method of estimating progression of chronic renal failure.

Authors:  W E Mitch; M Walser; G A Buffington; J Lemann
Journal:  Lancet       Date:  1976-12-18       Impact factor: 79.321

5.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

6.  Efficacy and safety of benazepril for advanced chronic renal insufficiency.

Authors:  Fan Fan Hou; Xun Zhang; Guo Hua Zhang; Di Xie; Ping Yan Chen; Wei Ru Zhang; Jian Ping Jiang; Min Liang; Guo Bao Wang; Zheng Rong Liu; Ren Wen Geng
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

7.  Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.

Authors:  Fan Fan Hou; Di Xie; Xun Zhang; Ping Yan Chen; Wei Ru Zhang; Min Liang; Zhi Jian Guo; Jian Ping Jiang
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

8.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

Authors:  G Maschio; D Alberti; G Janin; F Locatelli; J F Mann; M Motolese; C Ponticelli; E Ritz; P Zucchelli
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245

9.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  2 in total

Review 1.  Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.

Authors:  Min Jun; Tanvir Chowdhury Turin; Mark Woodward; Vlado Perkovic; Hiddo J Lambers Heerspink; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

2.  Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study.

Authors:  Cornelia Schneider; Blai Coll; Susan S Jick; Christoph R Meier
Journal:  Clin Epidemiol       Date:  2016-06-11       Impact factor: 4.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.